JP2000502318A - N−L−α−アスパルチル−L−フェニルアラニン1−メチルエステルの鎮痛剤としての使用 - Google Patents
N−L−α−アスパルチル−L−フェニルアラニン1−メチルエステルの鎮痛剤としての使用Info
- Publication number
- JP2000502318A JP2000502318A JP9503971A JP50397197A JP2000502318A JP 2000502318 A JP2000502318 A JP 2000502318A JP 9503971 A JP9503971 A JP 9503971A JP 50397197 A JP50397197 A JP 50397197A JP 2000502318 A JP2000502318 A JP 2000502318A
- Authority
- JP
- Japan
- Prior art keywords
- pain
- apm
- analgesic
- compound
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/31—Artificial sweetening agents containing amino acids, nucleotides, peptides or derivatives
- A23L27/32—Artificial sweetening agents containing amino acids, nucleotides, peptides or derivatives containing dipeptides or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Seasonings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳動物において疼痛を減少する方法であって、前記治療を必要とする前記 哺乳動物において疼痛を低下させる有効量の (ここで、RはH又は1〜6個の炭素を含むアルキルである)からなる化合物 を前記哺乳動物に投与することを含む前記方法。 2.前記化合物の前記有効量が約40mg〜約540mg であることを特徴とする請求項 1に記載の方法。 3.前記化合物の前記有効量が約80mg〜約320mg であることを特徴とする請求項 1に記載の方法。 4.前記化合物の前記有効量が約180mgであることを特徴とする請求項1に記載 の方法。 5.哺乳動物において疼痛に対する第1の鎮痛薬の投与量を減少する方法であっ て、前記治療を必要とする前記哺乳動物において疼痛を低下させる有効量の (ここで、RはH又は1〜6個の炭素を含むアルキルである)からなる第2の 化合物を前記哺乳動物に投与することを含む前記方法。 6.前記第1の鎮痛薬が、アセタミノフェン、フェナセチン、アスピリン、イブ プロフェン、フェニルブタゾン、インドメタシンおよび誘導体、アヘン剤およ び誘導体、ピロキサカム、並びにステロイド系および非ステロイド系抗炎症剤 からなる群から選択されることを特徴とする請求項5に記載の方法。 7.前記第2の化合物の前記有効量が約40mg〜約540mgであることを特徴とする 請求項5に記載の方法。 8.前記第2の化合物の前記有効量が約40mg〜約540mgであることを特徴とする 請求項6に記載の方法。 9.前記第2の化合物の有効量が、前記第1の鎮痛薬の有効用量を約25%〜約75 %減少させるのに必要な量であることを特徴とする請求項5に記載の方法。 10.前記第2の化合物の有効量が、前記第1の鎮痛薬の有効用量を約25%〜約75 %減少させるのに必要な量であることを特徴とする請求項6に記載の方法。 11.前記第2の化合物の有効量が、前記第1の鎮痛薬の有効用量を約10%〜約90 %減少させるのに必要な量であることを特徴とする請求項5に記載の方法。 12.前記第2の化合物の有効量が、前記第1の鎮痛薬の有効用量を約10%〜約90 %減少させるのに必要な量であることを特徴とする請求項6に記載の方法。 13.変形性関節症の哺乳動物の疼痛を治療する方法であって、前記哺乳動物にお いて疼痛を低下させる有効量の (ここで、RはH又はl〜6個の炭素を含むアルキルである)からなる化合物 を投与する段階を含む前記方法。 14.鎮痛作用を得るための投与に適合した投与単位剤型の医薬製剤であって、投 与単位あたり、鎮痛的に有効で無毒な量の (ここで、RはH又は1〜6個の炭素を含むアルキルである)からなる化合物 と、医薬担体とを含む前記医薬製剤。 15.前記有効で無毒な量が約40mg〜約540mgであることを特徴とする請求項14に 記載の医薬製剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47995P | 1995-06-23 | 1995-06-23 | |
US08/590,409 | 1996-01-25 | ||
US08/590,409 US5654334A (en) | 1995-06-23 | 1996-01-25 | Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester |
US60/000,479 | 1996-01-25 | ||
PCT/US1996/010716 WO1997000692A1 (en) | 1995-06-23 | 1996-06-21 | ANALGESIC USE OF N-L-α-ASPARTYL-L-PHENYLALANINE 1-METHYL ESTER |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000502318A true JP2000502318A (ja) | 2000-02-29 |
JP2000502318A5 JP2000502318A5 (ja) | 2004-08-05 |
Family
ID=26667704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9503971A Ceased JP2000502318A (ja) | 1995-06-23 | 1996-06-21 | N−L−α−アスパルチル−L−フェニルアラニン1−メチルエステルの鎮痛剤としての使用 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5654334A (ja) |
EP (1) | EP0833651B1 (ja) |
JP (1) | JP2000502318A (ja) |
AT (1) | ATE293986T1 (ja) |
AU (1) | AU722460B2 (ja) |
CA (1) | CA2225462A1 (ja) |
DE (1) | DE69634662T2 (ja) |
WO (1) | WO1997000692A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016331A1 (ja) * | 2003-08-13 | 2005-02-24 | Mochida Pharmaceutical Co., Ltd. | N−(ベンゾイル)アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654334A (en) * | 1995-06-23 | 1997-08-05 | Oklahoma Medical Research Foundation | Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester |
US6177467B1 (en) | 1996-09-26 | 2001-01-23 | Oklahoma Medical Research Foundation | Use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester and its derivatives in disease regression |
US6156795A (en) * | 1997-12-22 | 2000-12-05 | Oklahoma Medical Research Foundation | N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement |
US6326400B1 (en) | 1999-08-27 | 2001-12-04 | Allen B. Edmundson | N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement |
AUPQ291499A0 (en) * | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
US6919374B1 (en) | 1999-09-25 | 2005-07-19 | Oklahoma Medical Research Foundation | Viscosity modulating substance and use thereof |
AU773415B2 (en) * | 1999-09-25 | 2004-05-27 | Oklahoma Medical Research Foundation | Viscosity modulating substance and use thereof |
US7288527B2 (en) * | 2004-04-27 | 2007-10-30 | Oklahoma Medical Research Foundation | Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester |
WO2005123106A1 (en) * | 2004-06-10 | 2005-12-29 | Oklahoma Medical Research Foundation | Use of n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester to treat sunburn and other burns |
CN101410118A (zh) * | 2006-03-24 | 2009-04-15 | 惠氏公司 | 疼痛的治疗 |
US10272097B2 (en) | 2013-12-24 | 2019-04-30 | Virginia Commonwealth University | Uses of oxygenated cholesterol sulfates (OCS) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492131A (en) * | 1966-04-18 | 1970-01-27 | Searle & Co | Peptide sweetening agents |
US5053396A (en) * | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
IT1209667B (it) * | 1985-11-12 | 1989-08-30 | Zambon Spa | Composizione effeverscente adattivita' analgesica. |
AU620329B2 (en) * | 1987-04-09 | 1992-02-20 | Terumo Kabushiki Kaisha | B lymphocyte separating material and body fluid clarifying material |
JPH0832627B2 (ja) * | 1988-02-16 | 1996-03-29 | 三井東圧化学株式会社 | 二日酔予防治療剤 |
US5053393A (en) * | 1988-07-20 | 1991-10-01 | Monsanto Company | Novel platelet-aggregation inhibitor |
FR2649611A1 (fr) * | 1989-07-13 | 1991-01-18 | Philippe Perovitch | Procede de preparation galenique d'une composition therapeutique notamment a base d'aspirine |
IT1264856B1 (it) * | 1993-06-21 | 1996-10-17 | Zambon Spa | Composizione farmaceutica ad attivita' analgesica |
BE1007099A5 (fr) * | 1993-11-22 | 1995-03-14 | Messadek Jallal | Activite medicamenteuse de l'aspartame. |
FR2714064B1 (fr) * | 1993-12-16 | 1996-03-08 | Edmond Creppy | Aspartame pour son application en tant que substance thérapeutiquement active. |
US5654334A (en) * | 1995-06-23 | 1997-08-05 | Oklahoma Medical Research Foundation | Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester |
-
1996
- 1996-01-25 US US08/590,409 patent/US5654334A/en not_active Expired - Lifetime
- 1996-06-21 DE DE69634662T patent/DE69634662T2/de not_active Expired - Fee Related
- 1996-06-21 US US08/983,027 patent/US5998473A/en not_active Expired - Lifetime
- 1996-06-21 AT AT96921738T patent/ATE293986T1/de not_active IP Right Cessation
- 1996-06-21 JP JP9503971A patent/JP2000502318A/ja not_active Ceased
- 1996-06-21 WO PCT/US1996/010716 patent/WO1997000692A1/en active Search and Examination
- 1996-06-21 CA CA002225462A patent/CA2225462A1/en not_active Abandoned
- 1996-06-21 AU AU62878/96A patent/AU722460B2/en not_active Ceased
- 1996-06-21 EP EP96921738A patent/EP0833651B1/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016331A1 (ja) * | 2003-08-13 | 2005-02-24 | Mochida Pharmaceutical Co., Ltd. | N−(ベンゾイル)アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤 |
Also Published As
Publication number | Publication date |
---|---|
EP0833651A1 (en) | 1998-04-08 |
DE69634662T2 (de) | 2006-03-02 |
CA2225462A1 (en) | 1997-01-09 |
WO1997000692A1 (en) | 1997-01-09 |
AU722460B2 (en) | 2000-08-03 |
EP0833651B1 (en) | 2005-04-27 |
US5654334A (en) | 1997-08-05 |
ATE293986T1 (de) | 2005-05-15 |
DE69634662D1 (de) | 2005-06-02 |
AU6287896A (en) | 1997-01-22 |
US5998473A (en) | 1999-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1066038B1 (en) | Use of cabergoline in the treatment of restless legs syndrome | |
JP4898073B2 (ja) | 鼻内投与用フェンタニル組成物 | |
DeNucci et al. | Identifying a neurobiologic basis for drug therapy in TMDs | |
TWI331920B (en) | Unit dosage form for relieving or treating constipation in human patients | |
JP2000502318A (ja) | N−L−α−アスパルチル−L−フェニルアラニン1−メチルエステルの鎮痛剤としての使用 | |
CA2198833C (en) | Carnitine derivative-containing medicament for treating chronic arteriosclerosis obliterans | |
JPS59501460A (ja) | カフェインを含んで成る改良された鎮痛及び抗炎症組成物並びにその使用方法 | |
EP2138174A1 (en) | Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management | |
US7956091B2 (en) | Use of carnitines for the prevention and/or treatment of disorders caused by the andropause | |
TW202308653A (zh) | 以神經活性類固醇進行治療的方法 | |
US6326400B1 (en) | N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement | |
US6156795A (en) | N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement | |
Esmat et al. | Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy, a double-blind, placebo-controlled trial | |
JP2001526217A (ja) | 血管性頭痛に対する局所麻酔薬の新規な使用 | |
AU2005239799B2 (en) | Sustained-release oral molsidomine composition for treating atherosclerosis | |
Solomon, L. & Abrams | Bumadizone calcium in the treatment of rheumatoid arthritis | |
Baier et al. | 7 Restless legs syndrome and periodic limb movement disorder | |
EP1477168A1 (en) | Use of cabergoline in the treatment of restless leg syndrome | |
UA59481C2 (uk) | Спосіб лікування абстинентного синдрому у хворих з опійною залежністю |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040218 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040422 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040527 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050520 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060926 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070216 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070320 |